Evidence map›Paper›PMID 41853938›Full record

ArticleJournal of inherited metabolic disease2026

Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X-Linked Adrenoleukodystrophy.

Julia Lier, Markus Ponleitner, Denny Popp, Lisa Schäfer, Franziska Küstermann, Christof Meigen, Frank Kratzer, Joachim Janda, Jürgen Okun, Rami Abou Jamra and 2 more

Abstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julia LierDepartment of Neurology, University Medical Center, Leipzig, Germany.ORCID https://orcid.org/0000-0002-8454-9425
Markus PonleitnerDepartment of Neurology, University Medical Center, Leipzig, Germany.
Denny PoppInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Saxony, Germany.
Lisa SchäferDepartment of Neurology, University Medical Center, Leipzig, Germany.
Franziska KüstermannDepartment of Neurology, University Medical Center, Leipzig, Germany.
Christof MeigenLIFE Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Frank KratzerDivision of Neuropediatrics and Metabolic Medicine, Department of Pediatrics I, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Joachim JandaDivision of Neuropediatrics and Metabolic Medicine, Department of Pediatrics I, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-6293-0831
Jürgen OkunDivision of Neuropediatrics and Metabolic Medicine, Department of Pediatrics I, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Rami Abou JamraInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Saxony, Germany.
Wolfgang KöhlerDepartment of Neurology, University Medical Center, Leipzig, Germany.
Caroline BergnerDepartment of Neurology, University Medical Center, Leipzig, Germany.ORCID https://orcid.org/0000-0002-0327-1389

Funding

Bundesministerium für Gesundheit ZMVI1 -2520DAT94BDeutsche Forschungsgemeinschaft SPP2395Faculty of Medicine Leipzig, Clinician Scientist ProgrammeSächsische Aufbaubank 100601615
6 · The paper itself

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long-chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single-center study, we analyzed clinical and biochemical data from 364 patients with X-ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter-individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X-ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.

Indexed as

AdrenoleukodystrophyFatty AcidsAdolescentAdrenal InsufficiencyAdultAge of OnsetBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPhenotypeProspective StudiesRetrospective StudiesBiomarkersFatty Acidsdata registryleukodystrophynatural historyx‐ALD

Identifiers

PMID41853938
PMCPMC13000868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.